Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus

In Russia, sulfonylurea drugs are extensively prescribed to patients with type 2 diabetes mellitus. This work was designed to study pharmacoeconomicaspects of application of 2nd generation sulfonylureas based on the results of the GUIDE study comparing effects of therapy with gliclazide modifiedrele...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Alla Vsevolodovna Rudakova
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2011
Materias:	type 2 diabetes mellitus sulfonylureas hypoglycemia cost-effectiveness analysis Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/7fc1edfe2f104d5aae5849035a838ec8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7fc1edfe2f104d5aae5849035a838ec8
record_format	dspace
spelling	oai:doaj.org-article:7fc1edfe2f104d5aae5849035a838ec82021-11-14T09:00:16ZPharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus2072-03512072-037810.14341/2072-0351-6234https://doaj.org/article/7fc1edfe2f104d5aae5849035a838ec82011-09-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/6234https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378In Russia, sulfonylurea drugs are extensively prescribed to patients with type 2 diabetes mellitus. This work was designed to study pharmacoeconomicaspects of application of 2nd generation sulfonylureas based on the results of the GUIDE study comparing effects of therapy with gliclazide modifiedrelease (diabeton MV) and glimepiride (amaryl). The two drugs are known to be equally effective, but gliclazide creates a much smaller risk ofhypoglycemia than glymepiride. Cost-effectiveness analysis showed that the use of gliclazide cuts the costs of therapy by 40%. It is concluded that thechoice of gliclazide modified release is economically more feasible than glimepiride.Alla Vsevolodovna RudakovaEndocrinology Research Centrearticletype 2 diabetes mellitussulfonylureashypoglycemiacost-effectiveness analysisNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 14, Iss 3, Pp 111-112 (2011)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	type 2 diabetes mellitus sulfonylureas hypoglycemia cost-effectiveness analysis Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	type 2 diabetes mellitus sulfonylureas hypoglycemia cost-effectiveness analysis Nutritional diseases. Deficiency diseases RC620-627 Alla Vsevolodovna Rudakova Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
description	In Russia, sulfonylurea drugs are extensively prescribed to patients with type 2 diabetes mellitus. This work was designed to study pharmacoeconomicaspects of application of 2nd generation sulfonylureas based on the results of the GUIDE study comparing effects of therapy with gliclazide modifiedrelease (diabeton MV) and glimepiride (amaryl). The two drugs are known to be equally effective, but gliclazide creates a much smaller risk ofhypoglycemia than glymepiride. Cost-effectiveness analysis showed that the use of gliclazide cuts the costs of therapy by 40%. It is concluded that thechoice of gliclazide modified release is economically more feasible than glimepiride.
format	article
author	Alla Vsevolodovna Rudakova
author_facet	Alla Vsevolodovna Rudakova
author_sort	Alla Vsevolodovna Rudakova
title	Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
title_short	Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
title_full	Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
title_fullStr	Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
title_full_unstemmed	Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
title_sort	pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
publisher	Endocrinology Research Centre
publishDate	2011
url	https://doaj.org/article/7fc1edfe2f104d5aae5849035a838ec8
work_keys_str_mv	AT allavsevolodovnarudakova pharmacoeconomicaspectsoftheuseofsulfonylureadrugsintype2diabetesmellitus
_version_	1718429589889351680

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus

Ejemplares similares